{"id":"NCT00501046","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2007-07-13","resultsPosted":"2015-03-02","lastUpdate":"2022-06-07"},"enrollment":1015,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"AST-120","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"AST-120","type":"EXPERIMENTAL"}],"summary":"1\\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function and quality of life.","primaryOutcome":{"measure":"Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.","timeFrame":"Beyond Week 48, a 12-week visit cycle continued until the end of the study or until individual patients reached an endpoint","effectByArm":[{"arm":"AST-120","deltaMin":172,"sd":null},{"arm":"Placebo","deltaMin":183,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":106,"countries":["United States","Argentina","Brazil","Canada","Czechia","Germany","Mexico","Poland","Puerto Rico","Russia","Spain","Ukraine"]},"refs":{"pmids":["25349205","28741050","27716149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":156,"n":507},"commonTop":["Anaemia","Oedema peripheral","Hypertension","Constipation","Nausea"]}}